脑机接口概念拉升，爱朋医疗20%涨停，岩山科技4连板

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant momentum, driven by recent developments such as Neuralink's approval for clinical trials in Canada, which is expected to enhance market sentiment and investment opportunities in the industry [1] Industry Summary - The BCI concept saw a notable rise in stock prices, with companies like Aipeng Medical reaching a 20% limit up, and others like Yanshan Technology achieving four consecutive trading gains [1] - Neuralink, a company owned by Elon Musk, has received approval from the Canadian health authorities to initiate its first clinical trial in the country, focusing on the safety of its implants and surgical robots, as well as their functionality in helping quadriplegic patients control external devices with their thoughts [1] - According to CITIC Securities, BCI is considered one of the most promising directions for new productive forces, with both domestic and international companies actively promoting the commercialization of BCI across various sectors including healthcare, industry, and entertainment [1] - Domestic policies are placing significant emphasis on the development of the BCI industry, aiming to facilitate the application and transformation of BCI technologies [1] - Companies are striving to break foreign technological monopolies and establish a fully controllable, comprehensive industrial solution [1] Company Focus - Investment opportunities are suggested in companies that are likely to benefit from overseas breakthroughs in the BCI industry, which may elevate domestic market expectations [1] - Companies that are expected to launch consumer-grade BCI products are also highlighted as potential investment targets [1] - Firms that could benefit from the practical application of BCI products are recommended for attention [1]